Hodgkin Lymphoma Survivors: We Need to Do Better
Menée aux Pays-Bas à partir de données portant sur 4 919 patients atteints d'un lymphome Hodgkinien et ayant été traités avant l'âge de 51 ans sur la période 1965-2000, cette étude analyse les facteurs associés à la mortalité spécifique à long terme (durée médiane de suivi : 20,2 ans)
In this issue of JNCI, de Vries and colleagues examined the cause-specific late mortality among a multi-center Dutch cohort of Hodgkin lymphoma survivors. While this study examines a population that has been extensively examined, and we know carry a high-risk of chronic health conditions, subsequent malignant neoplasms (SMN) and premature mortality, the breadth and details included in this analysis further inform care of Hodgkin lymphoma survivors while supporting the need for development of novel approaches to treat patients with newly diagnosed Hodgkin lymphoma.
Journal of the National Cancer Institute , éditorial, 2019